Life science company BioDuro LLC revealed on Friday the election of Kent Payne, PhD as president of its CMC Global Solutions business.
Currently, Dr Payne is a board member for Goodwin Biotechnologies, a biological contract manufacturer, as well as board advisor for Vitruvias Therapeutics, a specialty generic pharmaceutical business.
Most recently, Dr Payne was employed as chief executive officer at Socorro Pharmaceuticals, a generic pharmaceutical company.
Previously, Dr Payne served as president Americas at Qualicaps Inc, principal consultant and partner at CoreFactor LLC and vice president/general manager at Catalent Pharma Solutions Inc. He has also held progressive leadership roles at Novartis, Monsanto and G.D. Searle.
Earlier, Dr Payne has held board and advisory roles at Life Science Institute Inc, a wholly-owned subsidiary of Mitsubishi Chemical Holdings, Technophar Inc, Qualicaps Inc and PDS Biotechnology (PDSB).
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical